Searched for
CIPLA INNOVATION
Zaynich's blockbuster potential lifts Wockhardt's long-term outlookWockhardt's novel antibiotic, Zaynich, has received USFDA approval after a 12-year effort, sparking hopes for a turnaround after years of n...- Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...
- Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...
- Is India Inc's CSR truly driving systemic change or just shifting funds?Corporate India is entering a new phase of CSR. Spending is expected to cross ₹1.2 lakh crore by 2035. Companies are shifting towards syste...
- Cohance Lifesciences shares rocket 43% in just 2 trading sessions. Here’s what is fuelling the surgeCohance Lifesciences shares surged over 43% in two days following the appointment of former Cipla CEO Umang Vohra as Executive Chairman and...
- Cohance Lifesciences shares skyrocket 20% on hiring former Cipla CEO Umang VohraShares of Cohance Lifesciences surged 20% on Monday after the appointment of former Cipla CEO Umang Vohra as its new Executive Chairman and...
- Sun Pharma closes in on Organon buy, gets set for $12 billion binding bidSun Pharmaceutical Industries is nearing a $12 billion acquisition of Organon & Co, marking its most significant overseas expansion. Follow...
- Mounjaro sales dip amid price war as semaglutide generics gain groundMounjaro, the star pharmaceutical from Eli Lilly, is experiencing a downturn in sales across India. This slump can be attributed to competi...
- Former Deloitte India chairman PR Ramesh joins VerSe Innovation as independent directorPR Ramesh, former Deloitte India chairman, has joined VerSe Innovation as an independent director and will chair its audit committee. He wi...
- Cipla plans deeper push in domestic market and chronic therapies over next 2–3 yearsCipla's incoming MD and CEO-designate, Achin Gupta, outlined a two-to-three-year strategy focusing on deepening the domestic market presenc...
- Cipla global CEO Umang Vohra to step down; Achin Gupta to take overCipla's global CEO Umang Vohra will step down in March 2026. Achin Gupta, currently global COO, will take over as the new MD and GCEO from ...
- Lilly, Cipla ink distribution pact for weight loss, type 2 diabetes treatment drug YurpeakIn an exciting collaboration, Cipla and Eli Lilly have unveiled Yurpeak, a groundbreaking diabetes and weight management medication, now av...
- Sanofi plans to launch 1 or 2 products in India every yearSanofi prioritizes the Indian market, focusing on diabetes, consumer health, and innovation. With a strategic shift under Hrosz's leadershi...
- Cipla invests in Ethris for mRNA-based inhalation therapiesThe investment will facilitate a long-term strategic partnership between Cipla and Ethris for the development of messenger RNA (mRNA)-based...
- Cipla to invest 15 million euros in Germany’s Ethris to expand respiratory portfolioThe investment will facilitate a long-term strategic partnership between Cipla and Ethris for development of messenger RNA (mRNA)-based the...
- Cipla ties up with Roche to sell 2 cancer drugs in IndiaThe pharma major will distribute Tocilizumab and Syndyma -- the second brand of Roche's cancer therapy bevacizumab -- in India.
- Delhi High Court quashes Cipla's appeal, says it can't market generics of Novartis' OnbrezThe court said it can't make a definitive conclusion that Novartis' imports of Onbrez were insufficient to meet the demands COPD patients f...
- Delhi HC upholds Roche's patent claims on Tarceva against CiplaIn a statement to ET, Roche said it welcomed the decision of the court, which has upheld the patent covering erlotinib hydrochloride.
- Cipla gets USFDA nod for Lopinavir, Ritonavir oral pelletsCipla has received approval from US health regulator USFDA for Lopinavir and Ritonavir oral pellets used for treating AIDS in infants and y...
- Cipla will stay close to innovation: Subhanu SaxenaSubhanu comes to Cipla with a diverse work experience across sectors, companies and locations such as Europe, North America, Africa and Asi...
Load More
